BOSTON, Massachusetts, USA and GHENT, Belgium, June 10, 2026
Orionis Biosciences and Novartis have announced a major multi-year strategic collaboration aimed at discovering and developing next-generation molecular glue medicines, strengthening efforts to unlock previously difficult-to-target disease pathways through proximity-based therapeutics. The expanded partnership will combine Orionis’ proprietary Allo-Glue™ platform and advanced AI-driven discovery engine with Novartis’ global drug development expertise to accelerate the identification, optimization, and advancement of novel molecular glue therapies across multiple disease areas. The agreement underscores growing pharmaceutical industry interest in induced-proximity drug discovery, a rapidly emerging field that enables precise modulation of disease-associated proteins through engineered molecular interactions. Under the collaboration, Orionis will receive an upfront payment of $40 million and is eligible for up to $1.4 billion in research, development, and commercial milestone payments, in addition to tiered royalties on future product sales, highlighting the significant commercial and scientific potential of the partnership.
AI-Driven Molecular Glue Platform Targets Challenging Diseases
At the center of the collaboration is Orionis’ innovative Allo-Glue™ platform, a technology designed to systematically discover and engineer molecular glue therapeutics capable of inducing targeted protein interactions inside living cells. Molecular glues represent one of the most promising new classes of medicines because they can influence proteins that have traditionally been considered difficult or impossible to target using conventional drug approaches. By leveraging artificial intelligence, chemical biology, and large-scale cellular screening technologies, Orionis has built an integrated discovery engine capable of identifying productive target-ligase pairs and rapidly optimizing molecular glue candidates.
The platform enables researchers to design therapies that can degrade, stabilize, or modulate disease-driving proteins with unprecedented precision. According to company leadership, recent advances in AI algorithms, robotic automation, and computational molecular design have dramatically accelerated every stage of molecular glue discovery, transforming what was once a highly empirical process into a scalable and rational drug development strategy.
Collaboration Expands Opportunities Across Multiple Therapeutic Areas
Advertisement
The expanded alliance reflects a shared commitment by both companies to advance innovative therapeutic modalities capable of addressing significant unmet medical needs. Under the agreement, Novartis and Orionis will collaborate to accelerate target identification, ligase profiling, molecular glue optimization, and translational research activities aimed at generating novel therapeutic candidates. The partnership builds on an existing relationship between the companies and reflects increasing confidence in the scientific potential of proximity-induced therapeutic approaches. Novartis researchers will gain access to Orionis’ proprietary discovery capabilities while contributing expertise in translational science, clinical development, and global commercialization.
The collaboration is expected to support programs spanning multiple disease areas, potentially including oncology, immunology, and other complex disorders where conventional drug development strategies have faced limitations. By combining advanced computational biology with innovative chemistry platforms, the companies aim to broaden the universe of druggable targets and create therapies capable of addressing previously inaccessible biological mechanisms.
Molecular Glue Medicines Emerging as a New Drug Discovery Frontier
The announcement highlights the growing momentum surrounding molecular glue therapeutics within the global biopharmaceutical industry. Unlike traditional small molecules that typically inhibit protein function, molecular glues work by creating or enhancing interactions between proteins, triggering specific biological outcomes that can selectively eliminate or regulate disease-causing targets. Industry experts increasingly view this approach as one of the most exciting frontiers in precision medicine because of its ability to expand therapeutic possibilities beyond conventional pharmacology.
Orionis, a clinical-stage biotechnology company, has established a diversified pipeline spanning oncology and immunology while continuing to refine its induced-proximity discovery technologies. For Novartis, the collaboration aligns with broader efforts to integrate artificial intelligence, advanced automation, and next-generation therapeutic platforms into drug discovery workflows. As pharmaceutical companies seek new ways to tackle challenging diseases and previously untreatable biological targets, partnerships focused on molecular glue technologies are expected to play a critical role in shaping the future of innovative medicine development.
Source: Novartis, Orionis Biosciences press release
